Decreased neutrophil–associated miRNA and increased B-cell associated miRNA expression during tuberculosis

Background: The basic studies have demonstrated that microRNA-204 (miRNA-204) was involved in the process of atherosclerosis and vascular calcification. However, the value of miRNA-204 as a predictive biomarker for cardiovascular disease (CVD) is still controversial. The purpose of the present study was to evaluate the association between circulating miRNA-204 level and the 10-year cardiovascular disease risk score, Framingham risk score (FRS).Method: The subjects consecutively enrolled 194 patients with type 2 diabetes mellitus without cardiovascular disease at Anzhen Hospital from January 2015 to September 2016. We used the Framingham Risk Score (FRS) to evaluate the risk of cardiovascular disease. Circulating miRNA-204 levels were measured by quantitative Real-Time polymerase chain reaction (qRT-PCR).Result: The circulating miRNA-204 levels were significantly lower in high risk group of CVD (FRS > 20%) of patients (0.49 ± 0.13) compared with that in low risk group (FRS < 10%) and intermediate risk group (FRS = 10%-20%) (0.87 ± 0.19, 0.75 ± 0.25, Respectively, p < 0.001). FRS was negatively correlated with miR-204 levels (r=-0.421, p < 0.001). According to multivariate logistic analyses, miRNA-204 levels were still significantly and independently associated with the high risk of CVD after adjusting the conventional risk factor. Receiver-operating characteristic curve (ROC) analysis also showed that circulating miRNA-204 level can predict the high risk of CVD, and the specificity was higher than traditional risk factors SBP and protective factor HDL-C of CVD.Conclusion: Our study demonstrated that patients with lower circulating miRNA-204 levels were at a high risk for the progression of CVD. After adjustment for potential confounders, miRNA-204 was independently associated with CVD in patients with T2DM.

show abstract

“…Furthermore, I.C. et al [27] reported that B-cell associated miRNA including miR-204-5p increases expression during active tuberculosis (TB).…”

Section: Microrna-204 Links To Multiple Diseasesmentioning

confidence: 99%

Serum microRNA-204 Levels are Associated with Long-Term Cardiovascular Diseases Risk Using Framingham Risk Score in Patients with Type 2 Diabetes: Results From an Observational Study

Wang

Ding

Pei

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…has-miR-197-3p, has-miR-99b-5p, and has-miR-191-5p are expressed higher in different patterns in the neutrophils of healthy controls vs. that in patients with active TB (124). miR320, miR204, miR-331, miR-147, and miR-210 expressions in B cells are differentially expressed between TB cases and controls, but the biological relevance of these findings is still uncertain (124).…”

Section: Detecting Progression To Active Tbmentioning

confidence: 99%

Diagnosis for Latent Tuberculosis Infection: New Alternatives

et al. 2020

View full text Add to dashboard Cite

Latent tuberculosis infection (LTBI) is a subclinical mycobacterial infection defined on the basis of cellular immune response to mycobacterial antigens. The tuberculin skin test (TST) and the interferon gamma release assay (IGRA) are currently used to establish the diagnosis of LTB. However, neither TST nor IGRA is useful to discriminate between active and latent tuberculosis. Moreover, these tests cannot be used to predict whether an individual with LTBI will develop active tuberculosis (TB) or whether therapy for LTBI could be effective to decrease the risk of developing active TB. Therefore, in this article, we review current approaches and some efforts to identify an immunological marker that could be useful in distinguishing LTBI from TB and in evaluating the effectiveness of treatment of LTB on the risk of progression to active TB.

show abstract

“…This approach might present limitations for the robustness and reproducibility of results. At variance, several other studies performed only qRT-PCR to validate candidate miRNA biomarkers identified from available datasets or based on the role of the candidate miRNA in TB pathogenesis [ 111 , 113 , 114 , 117 , 119 ].…”

Section: Biomarker Discovery Studiesmentioning

confidence: 99%

Tuberculosis-Associated MicroRNAs: From Pathogenesis to Disease Biomarkers

Sinigaglia

Peta

Riccetti

et al. 2020

Cells

View full text Add to dashboard Cite

Tuberculosis (TB) caused by Mycobacterium tuberculosis is one of the most lethal infectious diseases with estimates of approximately 1.4 million human deaths in 2018. M. tuberculosis has a well-established ability to circumvent the host immune system to ensure its intracellular survival and persistence in the host. Mechanisms include subversion of expression of key microRNAs (miRNAs) involved in the regulation of host innate and adaptive immune response against M. tuberculosis. Several studies have reported differential expression of miRNAs during active TB and latent tuberculosis infection (LTBI), suggesting their potential use as biomarkers of disease progression and response to anti-TB therapy. This review focused on the miRNAs involved in TB pathogenesis and on the mechanism through which miRNAs induced during TB modulate cell antimicrobial responses. An attentive study of the recent literature identifies a group of miRNAs, which are differentially expressed in active TB vs. LTBI or vs. treated TB and can be proposed as candidate biomarkers.

show abstract

Decreased neutrophil–associated miRNA and increased B-cell associated miRNA expression during tuberculosis

Cited by 21 publications

References 38 publications

Serum microRNA-204 Levels are Associated with Long-Term Cardiovascular Diseases Risk Using Framingham Risk Score in Patients with Type 2 Diabetes: Results From an Observational Study

Serum microRNA-204 Levels are Associated with Long-Term Cardiovascular Diseases Risk Using Framingham Risk Score in Patients with Type 2 Diabetes: Results From an Observational Study

Diagnosis for Latent Tuberculosis Infection: New Alternatives

Tuberculosis-Associated MicroRNAs: From Pathogenesis to Disease Biomarkers

Contact Info

Product

Resources

About